The Swiss contract development and manufacturing organization is the only CDMO with available large-scale U.S. mammalian capacity, according to William Blair analysts.
The Fishers campus expansion is expected to significantly increase sterile fill-finish output and support nearly 1,000 employees by the end of the decade.
